ePrivacy and GPDR Cookie Consent by Cookie Consent

Market Access & Post-Marketing

Enabling access to the best oncology treatments and care to everyone at the right price 

Scroll down to discover

We have developed solutions especially designed for your needs

Unique Diagnostic offer

Cutting-edge diagnostic tests covering multiple tumour biomarkers (DNA, RNA and proteins) in solid and liquid biopsies.

Unique Database

An up-to-date, comprehensive and proprietary database - OncoKDO - including gene variants information, drugs, clinical trials and scientific literature.

BioIT Platform

An industry-leading bio-IT SaaS integration & interpretation platform for healthcare professionals.

The Oncology Specialists

Access to our specialised oncology resources (scientific/genomic, clinical and outcomes data experts) and oncologists network.

Digital platform

A tailored and easy to access digital platform combining testing and digital patient/HCP data collection.

They trust our expertise

More testimonial videos
M.D. Ph.D. Antonio Gualberto
Head of Development and Chief Medical Officer
Kura Oncology - USA

"Aiding physicians to identify HRAS and other mutations in HNSCC is an essential element of Kura’s clinical development strategy. Streamlining screening processes facilitates timely access to important medical information that could help oncologists and their patients in making treatment decisions"

Dr. Alan L. HO
Memorial Sloan Kettering Cancer Center - USA

The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3. (ESMO 22 october 2018)